Illuminating Hope for Mental Health: A Drug Review on Lumateperone

This drug review provides a comprehensive analysis of a novel antipsychotic called lumateperone, marketed as Caplyta. Lumateperone gained FDA approval in 2019 for treating schizophrenia and later, in 2021, for treating bipolar depression. The review begins by delving into lumateperone's mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarzian, Martin, Ndrio, Mariana, Chique, Byron, Serai, Japjit, Thalackal, Bryce, Lau, Jessi, Fakoya, Adegbenro O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612995/
https://www.ncbi.nlm.nih.gov/pubmed/37900490
http://dx.doi.org/10.7759/cureus.46143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612995/
https://www.ncbi.nlm.nih.gov/pubmed/37900490
http://dx.doi.org/10.7759/cureus.46143

Ejemplares similares